Title
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis
Author
Killestein, J.
Hoogervorst, E.L.J.
Reif, M.
Blauw, B.
Smits, M.
Uitdehaag, B.M.J.
Nagelkerken, L.
Polman, C.H.
TNO Preventie en Gezondheid
Publication year
2003
Abstract
Cannabinoids can modulate the function of immune cells. We here present the first human in vivo study measuring immune function in 16 MS patients treated with oral cannabinoids. A modest increase of TNF-α in LPS-stimulated whole blood was found during cannabis plant-extract treatment (p=0.037), with no change in other cytokines. In the subgroup of patients with high adverse event scores, we found an increase in plasma IL-12p40 (p=0.002). The results suggest pro-inflammatory disease-modifying potential of cannabinoids in MS. © 2003 Elsevier Science B.V. All rights reserved. Chemicals/CAS: cannabis, 8001-45-4, 8063-14-7; dronabinol, 7663-50-5; Adjuvants, Immunologic; Cannabinoids; Plant Extracts; Tetrahydrocannabinol, 1972-08-3
Subject
Cytokines
THC
Dronabinol
Lipopolysaccharide
Tumor necrosis factor alpha
Ataxia
Clinical article
Controlled study
Drug effect
Headache
Immune function test
Immunomodulation
In vivo study
Mental instability
Somnolence
Spasticity
Vertigo
Xerostomia
Adjuvants, Immunologic
Administration, Oral
Adult
Cannabinoids
Cannabis
Confidence Intervals
Cross-Over Studies
Female
Humans
Male
Middle Aged
Multiple Sclerosis
Phytotherapy
Plant Extracts
Tetrahydrocannabinol
To reference this document use:
http://resolver.tudelft.nl/uuid:605056bb-49fe-4ce5-b080-29efd59517e7
DOI
https://doi.org/10.1016/s0165-5728(03)00045-6
TNO identifier
237029
ISSN
0165-5728
Source
Journal of Neuroimmunology, 137 (1-2), 140-143
Document type
article